Clinical Report: Exploring Androgenetic Alopecia in Transgender and Gender-Diverse Populations

Overview

Androgenetic alopecia (AGA) significantly impacts transgender and gender-diverse individuals, exacerbating gender dysphoria and affecting quality of life. Management strategies include individualized dosing of oral minoxidil and consideration of adjunctive treatments such as dutasteride or finasteride for transgender men.

Background

AGA is the most prevalent form of hair loss and poses unique challenges in transgender and gender-diverse populations, where it can influence gender expression and social recognition. The psychosocial ramifications of AGA in these individuals necessitate timely and effective management strategies. Understanding the interplay between hormone therapy and AGA is crucial for optimizing treatment outcomes.

Data Highlights

No numerical data was presented in the article.

Key Findings

• AGA is clinically relevant in transgender and gender-diverse individuals, impacting their quality of life.
• Oral minoxidil is recommended for all individuals with AGA, with dosing tailored to personal therapeutic goals.
• Higher doses of oral minoxidil may be beneficial for transgender men to promote beard and body hair growth.
• Spironolactone is a first-line antiandrogen for transgender women, while the use of 5-alpha reductase inhibitors requires careful evaluation.
• Management recommendations are based on evidence from TGD cohorts and extrapolated data from cisgender studies.

Clinical Implications

Clinicians should recognize AGA as a significant concern for transgender and gender-diverse patients, necessitating individualized treatment plans. Effective management can alleviate gender dysphoria and improve overall quality of life, highlighting the importance of a multidisciplinary approach in care.

Conclusion

The management of AGA in transgender and gender-diverse individuals requires a nuanced understanding of hormonal influences and individual patient goals. Ongoing research is essential to refine treatment strategies and improve outcomes in this population.

References

1. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Evaluating Cardiometabolic Risk in Transgender Populations: The Impact of Sex Hormones and Chromosomal Differences
2. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Influence of GnRH Analogues and Hormonal Treatments on Bone Structure in Transgender Populations
3. The ASCO Post, 2020 -- Case Series Study Explores Experiences of Transgender Patients With Cancer
4. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Further Data Against the Use of Cyproterone Acetate in Gender-Affirming Hormone Therapy Regimens
5. Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review, 2026
6. A Canadian Consensus on Androgenetic Alopecia: Approach and Management, 2025
7. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement, 2025
8. Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review | Dermatology and Therapy | Springer Nature Link
9. A Canadian Consensus on Androgenetic Alopecia: Approach and Management - Ian Landells, Eunice Chow, Aditya K. Gupta, Julio C. Jasso Olivares, Thusanth Thuraisingam, Renita Ahluwalia, Jerry K. L. Tan, Michelle Pratt, Geeta Yadav, Quinton Chivers, Noemie Vezina, Tristan Laforest, Elias Raad, Jayden Owen, Nour R. Dayeh, 2025
10. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement - PubMed